Get started
Author

Atila Yıldırım

Observed names: ATİLA YILDIRIM, Atila YILDIRIM, Atila Yildirim, Atilla Yıldırım, Yildirim A, Yıldırım, Atila
ORCID: 0000-0002-6067-5646
Observed ORCID: 0000-0002-6067-5646
OpenAlex ID: A5073340444
The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer
2022 · Evren Fidan, Atila Yildirim, et al. · Journal of the Pakistan Medical Association · 7
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
2022 · Emre Yekedüz, Mehmet Fatih Özbay, et al. · European Journal of Clinical Pharmacology · 5
PDF
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study
2025 · Taha Koray Sahin, Fatih Atalah, et al. · Frontiers in Immunology · 4
PDF
Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung
2024 · Mustafa Emre Duygulu, Esra Aşık, et al. · Revista da Associação Médica Brasileira · 4
CDK4/6 Inhibitor-Associated Mean Corpuscular Volume Change: A Potential Parameter for Predicting Survival in Metastatic Breast Cancer?
2024 · Atila Yildirim, Mustafa Emre Duygulu, et al. · Journal of College of Physicians And Surgeons Pakistan · 3
Evaluation of patient adherence with oral anticancer agents
2023 · SEHER NAZLI KAZAZ, ATİLA YILDIRIM · Journal of Cancer Research and Therapeutics · 3
Hearing Loss After the First Low Dose Administration of Cisplatin
2022 · Atila Yildirim, Evren Fidan, et al. · Journal of College of Physicians And Surgeons Pakistan · 3
PDF
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study
2025 · Salih Tunbekici, Gokhan Sahin, et al. · Discover Oncology · 2
PDF
Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group
2025 · Gökhan Şahin, Esmanur Kaplan Tüzün, et al. · International Journal of Cancer · 2
Anxiety Levels in Cancer Patients during the First Months of the COVID-19 Pandemic
2023 · Seher Nazlı KAZAZ, Atila YILDIRIM · Sağlık Bilimlerinde Değer · 2
PDF
Gingival Stimulation: An Important Metabolic Regulator?
2017 · Yildirim A, Atmaca H, et al. · Journal of Obesity and Overweight · 2
PDF
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Medicina · 1
Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
2023 · Seher Nazli Kazaz, Ali Caner Ozdover, et al. · Journal of College of Physicians And Surgeons Pakistan · 1
Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study
2026 · Orhun Akdogan, Enes Yesilbas, et al. · JCO Oncology Practice
Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study
2026 · Zeynep Sıla Gökdere, Taha Koray Şahin, et al. · Targeted Oncology
Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
2026 · Emre Çakır, Didem Divriklioğlu, et al. · International Journal of Cancer
PDF
Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study
2026 · Esma Uguztemur, Ozgur Arici, et al. · Scientific Reports
PDF
Prognostic Significance of mEASIX, Inflammatory–Nutritional Biomarkers, Metastatic Patterns, and Treatment Characteristics in Metastatic Melanoma: A Multicenter Real-World Cohort Study
2026 · Şuheda Ataş İpek, Şendağ Yaslıkaya, et al. · Research Square
Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501)
2026 · Erman Akkus, Mehmet Kayaalp, et al. · International Journal of Cancer
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study
2026 · Suheda Atas Ipek, Sendag Yaslikaya, et al. · Journal of Clinical Medicine
PDF
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study
2026 · Bahadır Köylü, Özde Melisa Celayir, et al. · Cancers
Effect of "watch and wait" on fear of recurrence in rectal cancer: A multicenter cross-sectional study.
2026 · Ahmet Oruc, Galip Can Uyar, et al. · Journal of Clinical Oncology
PDF
The 100 most cited articles in ESR1 mutant breast cancer: a bibliometric analysis
2026 · Atila Yıldırım, Mustafa Emre Duygulu, et al. · Turkish Journal of Clinics and Laboratory
PDF
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group
2026 · Sedat Yıldız, Hacer Demir, et al. · Journal of Clinical Medicine
PDF
Retrospective analysis of tumor spread through air spaces (STAS) in non-small cell lung cancer (NSCLC) cases
2026 · Mustafa Emre Duygulu, Atila Yıldırım, et al. · Turkish Journal of Clinics and Laboratory
PDF
Works count: 35
Citation count: 39
H-index: 4
I10-index:
Year
Topic
Type